百时美施贵宝Bristol Myers Squibb（BMY）2025年第三季度财务业绩演示报告「NYSE」（英文版）（16页）.pdf

1、Not for Product Promotional UseQ3 2025 ResultsOctober 30,2025Not for Product Promotional UseQ3 2025 ResultsForward Looking Statements and Non-GAAP Financial Information 2This presentation contains statements about Bristol-Myers Squibb Companys(the“Company”)future financial results,plans,business dev

2、elopment strategy,anticipated clinical trials,results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.All statements that are not statements of historical facts are,or may be dee

3、med to be,forward-looking statements.Actual results may differ materially from those expressed in,or implied by,these statements as a result of various factors,including,but not limited to:(i)new laws,government actions and regulations,including with respect to pricing controls and market access and

4、 the imposition of new tariffs,trade restrictions and export regulations,including the potential for international reference pricing and most-favored nation drug pricing for our products,(ii)our ability to obtain,protect and maintain market exclusivity rights and enforce patents and other intellectu

5、al property rights,(iii)our ability to achieve expected clinical,regulatory and contractual milestones on expected timelines or at all,(iv)difficulties or delays in the development and commercialization of new products,(v)difficulties or delays in our clinical trials and the manufacturing,distributi

6、on and sale of our products,(vi)adverse outcomes in legal or regulatory proceedings,(vii)risks relating to acquisitions,divestitures,alliances,joint ventures and other portfolio actions and(viii)political and financial instability,including changes in general economic conditions.These and other impo